Who Paid My Doc
Phase II dose finding trial in monotherapy for MDD
Research payments
$1,111,742
Through program year 2025, $1,111,742 in research payments was reported against Phase II dose finding trial in monotherapy for MDD, across 172 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $969,162 | 130 |
| 2024 | Research | $142,580 | 42 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Michael Downing Dallas, TX Named on 17 payments
- Hinda Dubin Baltimore, MD Named on 16 payments
- Neeraj Gupta Long Beach, CA Named on 12 payments
- Shivkumar Hatti Media, PA Named on 12 payments
- Elias Sarkis Gainesville, FL Named on 10 payments
- Benny Barnhart Wichita Falls, TX Named on 10 payments
- Saundra Maass-Robinson Atlanta, GA Named on 9 payments
- David Purselle Atlanta, GA Named on 7 payments
- Irina Mezhebovsky Brookline, MA Named on 7 payments
- Gregory Mattingley Saint Charles, MO Named on 6 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.